The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Shanghai Henlius Biotech
Related studies linked through entity extraction aliases.
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation
- Status
- UNKNOWN
- Phase
- PHASE2
The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation
- Status
- UNKNOWN
- Phase
- PHASE2
The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment
- Status
- UNKNOWN
- Phase
- PHASE2
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation
- Status
- UNKNOWN
- Phase
- PHASE2
Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
- Status
- COMPLETED
- Phase
- PHASE3
Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE1
Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis
- Status
- UNKNOWN
- Phase
- PHASE2
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
- Status
- WITHDRAWN
- Phase
- PHASE3
A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor
- Status
- WITHDRAWN
- Phase
- PHASE1
A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
- Status
- COMPLETED
- Phase
- PHASE3
Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.
- Status
- WITHDRAWN
- Phase
- PHASE3
A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male Subjects
- Status
- COMPLETED
- Phase
- PHASE1